Company
ResApp Health Limited
Headquarters: Brisbane, QLD, Australia
Employees: 500
CEO: Dr. Anthony Keating
Market Cap
A$176.2 Million
AUD as of Sept. 1, 2022
US$120.1 Million
ResApp Health Limited Categories
Australia Healthcare Health Information ServicesAustralia Healthcare Australia Health Information Services
Top Competitors by Market Capitalization
Industry: Health Information Services
| Company | Market Cap (USD) |
|---|---|
| GE HealthCare | $38.72 B |
| Veeva Systems Inc. | $36.20 B |
| HealthEquity, Inc. | $9.07 B |
| Change Healthcare Inc. | $9.03 B |
| Pro Medicus Limited | $8.96 B |
Sector:
| Company | Market Cap (USD) |
|---|---|
| Lilly | $689.42 B |
| Novo Nordisk | $622.07 B |
| UnitedHealth Group | $487.54 B |
| Johnson & Johnson | $353.05 B |
| AbbVie | $301.60 B |
Detailed Description
ResApp Health Limited develops digital healthcare solutions to assist doctors and allow patients to diagnose and manage respiratory disease. The company offers ResAppDx, a smartphone-based acute respiratory disease diagnostic test for use in telehealth, emergency department, and primary care markets; and SleepCheck, a smartphone application that allows consumers to self-assess the risk of sleep apnoea. Its technology uses sound to diagnose respiratory diseases, including pneumonia, bronchiolitis, bronchitis, chronic obstructive pulmonary disease, and asthma. ResApp Health Limited has a joint development and pilot agreement with Medgate AG to integrate and test smartphone-based acute respiratory diagnostic test. The company was formerly known as Narhex Life Sciences Limited. ResApp Health Limited was incorporated in 2000 and is headquartered in Brisbane, Australia.
Stocks & Indices
ResApp Health Limited has the following listings and related stock indices.
Stock: ASX: RAP wb_incandescent